Morgan Stanley Prothena Corp Public LTD CO Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Morgan Stanley holds 719,988 shares of PRTA stock, worth $3.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

719,988

Previous 719,490 0.07%

Holding current value

$3.78 Million

Previous $9.96 Million 10.55%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$12.38 - $16.04 $6,165 - $7,987	498 Added 0.07%	719,988 $8.91 Million
Q4 2024 Feb 14, 2025	BUY	$11.95 - $18.35 $2,425 - $3,725	203 Added 0.03%	719,490 $9.96 Million
Q3 2024 May 14, 2025	SELL	$16.73 - $24.79 $1.53 Million - $2.27 Million	-91,416 Reduced 11.28%	719,287 $12 Million
Q3 2024 Nov 14, 2024	SELL	$16.73 - $24.79 $1.53 Million - $2.27 Million	-91,416 Reduced 11.28%	719,287 $12 Million
Q2 2024 May 14, 2025	BUY	$19.54 - $26.15 $1.78 Million - $2.39 Million	91,213 Added 12.68%	810,703 $16.7 Million
Q2 2024 Oct 17, 2024	BUY	$19.54 - $26.15 $3.09 Million - $4.14 Million	158,235 Added 24.25%	810,703 $16.7 Million
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $3.09 Million - $4.14 Million	158,235 Added 24.25%	810,703 $16.7 Million
Q1 2024 Oct 17, 2024	SELL	$24.75 - $40.66 $3.92 Million - $6.43 Million	-158,235 Reduced 19.52%	652,468 $16.2 Million
Q1 2024 Aug 16, 2024	BUY	$24.75 - $40.66 $4.21 Million - $6.92 Million	170,208 Added 35.29%	652,468 $16.2 Million
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $4.21 Million - $6.92 Million	170,208 Added 35.29%	652,468 $16.2 Million
Q4 2023 Aug 16, 2024	SELL	$32.31 - $52.32 $10.6 Million - $17.2 Million	-328,443 Reduced 40.51%	482,260 $17.5 Million
Q4 2023 Feb 13, 2024	BUY	$32.31 - $52.32 $6.89 Million - $11.2 Million	213,400 Added 79.37%	482,260 $17.5 Million
Q3 2023 Nov 15, 2023	BUY	$47.3 - $70.6 $5.5 Million - $8.21 Million	116,265 Added 76.19%	268,860 $13 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $6.39 Million - $10.4 Million	-132,312 Reduced 46.44%	152,595 $10.4 Million
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $4.91 Million - $6.09 Million	104,504 Added 57.93%	284,907 $13.8 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $723,703 - $903,760	13,904 Added 8.35%	180,403 $10.9 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $4.68 Million - $11.3 Million	-186,083 Reduced 52.78%	166,499 $10.1 Million
Q2 2022 Oct 27, 2022	BUY	$22.73 - $39.98 $69,576 - $122,378	3,061 Added 0.88%	352,582 $9.57 Million
Q2 2022 Aug 15, 2022	BUY	$22.73 - $39.98 $69,576 - $122,378	3,061 Added 0.88%	352,582 $9.57 Million
Q1 2022 Oct 27, 2022	SELL	$30.27 - $49.22 $92,656 - $150,662	-3,061 Reduced 0.87%	349,521 $12.8 Million
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $5.15 Million - $8.37 Million	169,990 Added 94.69%	349,521 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $4.94 Million - $8.6 Million	117,351 Added 188.73%	179,531 $8.87 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $3 Million - $4.91 Million	62,180 New	62,180 $4.43 Million

Others Institutions Holding PRTA

# of Institutions

185

Shares Held

43.7M

Call Options Held

251K

Put Options Held

79.2K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $246M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account